Loxapine

CHEMBL831 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

327.8 g/mol

LogP

3.1

Phase

4

A first-generation antipsychotic used to treat schizophrenia and acute agitation in bipolar disorder, available in inhaled form for rapid sedation. It blocks dopamine and serotonin receptors to reduce psychotic symptoms.

Masse moléculaire

327,8000 g/mol

LogP

3,10

TPSA

28,10 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Asthma Chronic Obstructive Pulmonary Disease Migraine Schizophrenia Bipolar Disorder Stroke Obesity

Mécanisme d'action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1

InChI

InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3

Molecular Formula

C18H18ClN3O

HBD / HBA

- / 3

Liaisons Rotatives

1

Atomes Lourds

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A first-generation antipsychotic used to treat schizophrenia and acute agitation in bipolar disorder, available in inhaled form for rapid sedation. It blocks dopamine and serotonin receptors to reduce psychotic symptoms.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Loxapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL831. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3964. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Loxapine sur PillFYI

Structure

Données Clés

Formule: C18H18ClN3O

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.